CA2872961A1 - Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof - Google Patents
Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof Download PDFInfo
- Publication number
- CA2872961A1 CA2872961A1 CA2872961A CA2872961A CA2872961A1 CA 2872961 A1 CA2872961 A1 CA 2872961A1 CA 2872961 A CA2872961 A CA 2872961A CA 2872961 A CA2872961 A CA 2872961A CA 2872961 A1 CA2872961 A1 CA 2872961A1
- Authority
- CA
- Canada
- Prior art keywords
- sbv
- cells
- sequence
- seq
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000660220 Schmallenberg virus Species 0.000 title claims abstract description 277
- 229960005486 vaccine Drugs 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims description 100
- 238000004519 manufacturing process Methods 0.000 title claims description 45
- 230000036244 malformation Effects 0.000 claims abstract description 24
- 206010058874 Viraemia Diseases 0.000 claims abstract description 23
- 230000005540 biological transmission Effects 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 152
- 239000000203 mixture Substances 0.000 claims description 113
- 241001465754 Metazoa Species 0.000 claims description 85
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 76
- 230000002163 immunogen Effects 0.000 claims description 68
- 150000007523 nucleic acids Chemical group 0.000 claims description 60
- 241000700605 Viruses Species 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 241000238631 Hexapoda Species 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 31
- 238000003306 harvesting Methods 0.000 claims description 28
- 230000002779 inactivation Effects 0.000 claims description 27
- 210000004962 mammalian cell Anatomy 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- -1 aziridine compound Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 244000144980 herd Species 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002612 dispersion medium Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 241001494479 Pecora Species 0.000 abstract description 39
- 241000283690 Bos taurus Species 0.000 abstract description 33
- 241000282849 Ruminantia Species 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 8
- 241000283707 Capra Species 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 59
- 208000015181 infectious disease Diseases 0.000 description 51
- 230000002458 infectious effect Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 17
- 238000006386 neutralization reaction Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 11
- 241000713112 Orthobunyavirus Species 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 241001222053 Akabane virus Species 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001493158 Simbu orthobunyavirus Species 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 241000238421 Arthropoda Species 0.000 description 3
- 241000283903 Ovis aries Species 0.000 description 3
- 206010036172 Porencephaly Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 239000004133 Sodium thiosulphate Substances 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- 241000713131 Aino virus Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000255930 Chironomidae Species 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000059498 Douglas virus Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010023509 Kyphosis Diseases 0.000 description 2
- 208000007623 Lordosis Diseases 0.000 description 2
- 206010050183 Macrocephaly Diseases 0.000 description 2
- 208000005767 Megalencephaly Diseases 0.000 description 2
- 241000250439 Oropouche virus Species 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 208000000705 Rift Valley Fever Diseases 0.000 description 2
- 241000059503 Sathuperi orthobunyavirus Species 0.000 description 2
- 241000059525 Shamonda orthobunyavirus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000018197 inherited torticollis Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002888 pairwise sequence alignment Methods 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 206010039722 scoliosis Diseases 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000282815 Antilocapra americana Species 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- 241000283700 Boselaphus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 208000008371 Bunyaviridae Infections Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000134426 Ceratopogonidae Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 241000134316 Culicoides <genus> Species 0.000 description 1
- 241000202315 Culicoides variipennis Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 238000010629 Molecular evolutionary genetics analysis Methods 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 201000006968 Oropouche fever Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 101150002378 gC gene Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009340 pathogen transmission Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12061—Methods of inactivation or attenuation
- C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170631 | 2012-06-01 | ||
| EP12170631.1 | 2012-06-01 | ||
| EP13157875 | 2013-03-05 | ||
| EP13157875.9 | 2013-03-05 | ||
| PCT/US2013/043146 WO2013181270A1 (en) | 2012-06-01 | 2013-05-29 | Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2872961A1 true CA2872961A1 (en) | 2013-12-05 |
Family
ID=48607368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2872961A Pending CA2872961A1 (en) | 2012-06-01 | 2013-05-29 | Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9370562B2 (enExample) |
| EP (1) | EP2855513B1 (enExample) |
| JP (1) | JP6250649B2 (enExample) |
| CN (1) | CN104350066B (enExample) |
| AR (1) | AR091240A1 (enExample) |
| AU (1) | AU2013267453C1 (enExample) |
| BR (1) | BR112014029515A2 (enExample) |
| CA (1) | CA2872961A1 (enExample) |
| DK (1) | DK2855513T3 (enExample) |
| EA (1) | EA034543B1 (enExample) |
| ES (1) | ES2617351T3 (enExample) |
| IN (1) | IN2014DN08927A (enExample) |
| MX (1) | MX363044B (enExample) |
| PL (1) | PL2855513T3 (enExample) |
| SG (1) | SG11201407619SA (enExample) |
| UY (1) | UY34840A (enExample) |
| WO (1) | WO2013181270A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6250649B2 (ja) | 2012-06-01 | 2017-12-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
| EP2855512B1 (en) | 2012-06-01 | 2018-02-28 | Boehringer Ingelheim Vetmedica GmbH | Genomic sequences of schmallenberg virus and uses thereof |
| HK1216006A1 (zh) * | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| CN104232587B (zh) * | 2014-09-02 | 2016-08-17 | 中国检验检疫科学研究院 | 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0811736B2 (ja) * | 1986-08-07 | 1996-02-07 | 財団法人化学及血清療法研究所 | 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン |
| GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
| US6114108A (en) | 1995-08-29 | 2000-09-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of viral nucleic acids |
| US20080226682A1 (en) * | 2007-03-13 | 2008-09-18 | Peros Systems Technologies, Inc. | Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents |
| EP2062594A1 (en) | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| JP6250649B2 (ja) | 2012-06-01 | 2017-12-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用 |
| EP2855512B1 (en) | 2012-06-01 | 2018-02-28 | Boehringer Ingelheim Vetmedica GmbH | Genomic sequences of schmallenberg virus and uses thereof |
-
2013
- 2013-05-29 JP JP2015515159A patent/JP6250649B2/ja not_active Expired - Fee Related
- 2013-05-29 AU AU2013267453A patent/AU2013267453C1/en not_active Ceased
- 2013-05-29 SG SG11201407619SA patent/SG11201407619SA/en unknown
- 2013-05-29 IN IN8927DEN2014 patent/IN2014DN08927A/en unknown
- 2013-05-29 CA CA2872961A patent/CA2872961A1/en active Pending
- 2013-05-29 EA EA201401352A patent/EA034543B1/ru not_active IP Right Cessation
- 2013-05-29 ES ES13728288.5T patent/ES2617351T3/es active Active
- 2013-05-29 MX MX2014014521A patent/MX363044B/es unknown
- 2013-05-29 EP EP13728288.5A patent/EP2855513B1/en active Active
- 2013-05-29 CN CN201380028863.3A patent/CN104350066B/zh active Active
- 2013-05-29 WO PCT/US2013/043146 patent/WO2013181270A1/en not_active Ceased
- 2013-05-29 DK DK13728288.5T patent/DK2855513T3/en active
- 2013-05-29 US US13/904,752 patent/US9370562B2/en active Active
- 2013-05-29 PL PL13728288T patent/PL2855513T3/pl unknown
- 2013-05-29 BR BR112014029515A patent/BR112014029515A2/pt not_active IP Right Cessation
- 2013-05-31 AR ARP130101936 patent/AR091240A1/es not_active Application Discontinuation
- 2013-05-31 UY UY0001034840A patent/UY34840A/es unknown
-
2016
- 2016-05-19 US US15/158,790 patent/US9872897B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9872897B2 (en) | 2018-01-23 |
| AU2013267453A1 (en) | 2014-11-13 |
| EP2855513A1 (en) | 2015-04-08 |
| ES2617351T3 (es) | 2017-06-16 |
| JP2015519367A (ja) | 2015-07-09 |
| JP6250649B2 (ja) | 2017-12-20 |
| EA201401352A1 (ru) | 2015-05-29 |
| CN104350066A (zh) | 2015-02-11 |
| AU2013267453B2 (en) | 2017-04-06 |
| US9370562B2 (en) | 2016-06-21 |
| UY34840A (es) | 2013-12-31 |
| EP2855513B1 (en) | 2016-12-07 |
| PL2855513T3 (pl) | 2017-05-31 |
| WO2013181270A1 (en) | 2013-12-05 |
| EA034543B1 (ru) | 2020-02-19 |
| DK2855513T3 (en) | 2017-03-13 |
| US20160250317A1 (en) | 2016-09-01 |
| AR091240A1 (es) | 2015-01-21 |
| BR112014029515A2 (pt) | 2017-07-25 |
| SG11201407619SA (en) | 2014-12-30 |
| US20130323277A1 (en) | 2013-12-05 |
| IN2014DN08927A (enExample) | 2015-05-22 |
| CN104350066B (zh) | 2018-06-19 |
| AU2013267453C1 (en) | 2017-08-10 |
| MX363044B (es) | 2019-03-06 |
| MX2014014521A (es) | 2015-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12290557B2 (en) | Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus | |
| TWI781962B (zh) | 抗豬小病毒疫苗 | |
| CN1152878A (zh) | 经改良修饰的brsv或疫苗 | |
| JP7587612B2 (ja) | 改変ｐｅｄｖスパイクタンパク質 | |
| TW201828982A (zh) | 抗豬小病毒及豬生殖與呼吸道症候群病毒之疫苗及其製造方法 | |
| US9872897B2 (en) | Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof | |
| WO2017123201A1 (en) | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus | |
| EP2187962A2 (en) | Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures | |
| Kamaraj et al. | Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis. | |
| CN1929859A (zh) | 抗睾丸bvdv感染的疫苗接种方法 | |
| El-Bagoury et al. | Efficacy of inactivated BEF vaccine adjuvant with Montanide ISA 206 compared with the locally prepared inactivated BEF vaccines | |
| CA2397861C (en) | Vaccination against canine herpesvirosis and vaccines therefor | |
| HK40059925A (en) | Novel vaccine compositions for porcine epidemic diarrhea virus | |
| Bhat et al. | Enhanced Immune Responses and Protection Against Viral Challenge in Sheep with a Novel Nanoemulsion-Based Inactivated Bluetongue Virus Vaccine | |
| HK1104171A (en) | Method of vaccination against testicular bvdv infection | |
| Federico et al. | Preliminary results on innocuity and efficacy of an inactivated PPR vaccine | |
| EA044956B1 (ru) | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180524 |
|
| EEER | Examination request |
Effective date: 20180524 |
|
| EEER | Examination request |
Effective date: 20180524 |
|
| EEER | Examination request |
Effective date: 20180524 |
|
| EEER | Examination request |
Effective date: 20180524 |
|
| EEER | Examination request |
Effective date: 20180524 |
|
| EEER | Examination request |
Effective date: 20180524 |